| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lysophospholipids | 49 | 2021 | 69 | 7.930 |
Why?
|
| Phosphatidate Phosphatase | 19 | 2024 | 23 | 4.340 |
Why?
|
| Phosphoric Diester Hydrolases | 24 | 2021 | 48 | 3.290 |
Why?
|
| Polychlorinated Biphenyls | 17 | 2021 | 35 | 3.170 |
Why?
|
| Environmental Pollutants | 13 | 2025 | 106 | 2.910 |
Why?
|
| Fluorocarbons | 6 | 2025 | 61 | 2.620 |
Why?
|
| Sphingosine | 16 | 2019 | 34 | 2.260 |
Why?
|
| Signal Transduction | 36 | 2023 | 1671 | 2.150 |
Why?
|
| Lipids | 9 | 2025 | 155 | 1.810 |
Why?
|
| Atherosclerosis | 11 | 2024 | 219 | 1.770 |
Why?
|
| Phospholipase D | 6 | 2020 | 11 | 1.750 |
Why?
|
| Animals | 116 | 2025 | 13505 | 1.740 |
Why?
|
| Inflammation | 12 | 2022 | 641 | 1.650 |
Why?
|
| Mice | 79 | 2024 | 5949 | 1.450 |
Why?
|
| Sphingolipids | 6 | 2019 | 18 | 1.220 |
Why?
|
| Ceramides | 10 | 2024 | 34 | 1.200 |
Why?
|
| Alkanesulfonic Acids | 4 | 2025 | 10 | 1.190 |
Why?
|
| Mice, Inbred C57BL | 44 | 2024 | 1884 | 1.180 |
Why?
|
| Tandem Mass Spectrometry | 6 | 2021 | 251 | 1.170 |
Why?
|
| Lipid Metabolism | 9 | 2022 | 187 | 1.120 |
Why?
|
| Plasma | 2 | 2025 | 45 | 1.080 |
Why?
|
| Cell Movement | 15 | 2020 | 268 | 1.000 |
Why?
|
| Polyisoprenyl Phosphates | 4 | 2014 | 13 | 0.970 |
Why?
|
| Humans | 110 | 2025 | 52483 | 0.960 |
Why?
|
| Chromatography, Liquid | 3 | 2021 | 240 | 0.960 |
Why?
|
| Mice, Knockout | 29 | 2024 | 879 | 0.960 |
Why?
|
| Blood Specimen Collection | 1 | 2025 | 35 | 0.930 |
Why?
|
| Capillaries | 1 | 2025 | 50 | 0.930 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 490 | 0.920 |
Why?
|
| Veins | 1 | 2025 | 74 | 0.900 |
Why?
|
| Multienzyme Complexes | 5 | 2010 | 40 | 0.870 |
Why?
|
| Diet | 5 | 2024 | 587 | 0.860 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2023 | 2 | 0.860 |
Why?
|
| Plaque, Atherosclerotic | 4 | 2024 | 44 | 0.840 |
Why?
|
| Pyrophosphatases | 6 | 2011 | 17 | 0.810 |
Why?
|
| Blood Platelets | 10 | 2020 | 259 | 0.810 |
Why?
|
| Streptomyces | 9 | 2016 | 10 | 0.800 |
Why?
|
| Choline | 2 | 2020 | 64 | 0.770 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2020 | 133 | 0.760 |
Why?
|
| Adipocytes | 8 | 2021 | 132 | 0.750 |
Why?
|
| Drinking Water | 1 | 2021 | 13 | 0.730 |
Why?
|
| Glucose | 8 | 2022 | 355 | 0.730 |
Why?
|
| Phosphodiesterase I | 5 | 2010 | 5 | 0.730 |
Why?
|
| Diet, High-Fat | 8 | 2021 | 236 | 0.700 |
Why?
|
| Receptors, LDL | 4 | 2024 | 71 | 0.690 |
Why?
|
| Phosphatidic Acids | 3 | 2020 | 8 | 0.670 |
Why?
|
| Phosphoric Monoester Hydrolases | 6 | 2022 | 23 | 0.670 |
Why?
|
| Drosophila melanogaster | 2 | 2019 | 32 | 0.670 |
Why?
|
| Integrins | 4 | 2020 | 31 | 0.660 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 52 | 0.630 |
Why?
|
| Myocardium | 7 | 2020 | 453 | 0.620 |
Why?
|
| Obesity | 11 | 2021 | 1162 | 0.600 |
Why?
|
| NF-kappa B | 3 | 2019 | 322 | 0.600 |
Why?
|
| Liver | 9 | 2023 | 1156 | 0.600 |
Why?
|
| Insulin Resistance | 9 | 2023 | 275 | 0.590 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 1222 | 0.590 |
Why?
|
| Adipogenesis | 3 | 2018 | 49 | 0.580 |
Why?
|
| Methylamines | 4 | 2019 | 20 | 0.570 |
Why?
|
| Molecular Structure | 15 | 2020 | 314 | 0.550 |
Why?
|
| Male | 52 | 2025 | 26761 | 0.550 |
Why?
|
| Homeostasis | 7 | 2021 | 201 | 0.550 |
Why?
|
| Cytokines | 4 | 2022 | 623 | 0.540 |
Why?
|
| Pregnancy Trimester, First | 1 | 2017 | 23 | 0.540 |
Why?
|
| Enzyme Inhibitors | 8 | 2017 | 372 | 0.530 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 59 | 0.520 |
Why?
|
| Neoplasms | 5 | 2024 | 1325 | 0.480 |
Why?
|
| Cells, Cultured | 15 | 2019 | 1567 | 0.470 |
Why?
|
| Adipose Tissue | 7 | 2019 | 204 | 0.470 |
Why?
|
| Receptors, Lysophosphatidic Acid | 9 | 2021 | 11 | 0.460 |
Why?
|
| Dioxins | 3 | 2020 | 11 | 0.460 |
Why?
|
| Micelles | 3 | 2022 | 8 | 0.460 |
Why?
|
| Myocardial Infarction | 4 | 2022 | 412 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 807 | 0.440 |
Why?
|
| Protein Prenylation | 2 | 2013 | 5 | 0.440 |
Why?
|
| Receptors, Aryl Hydrocarbon | 4 | 2019 | 28 | 0.440 |
Why?
|
| Enzymes | 3 | 2013 | 29 | 0.440 |
Why?
|
| Farnesol | 1 | 2013 | 4 | 0.430 |
Why?
|
| Mevalonic Acid | 1 | 2013 | 5 | 0.430 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2022 | 93 | 0.420 |
Why?
|
| Diterpenes | 1 | 2013 | 31 | 0.420 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2014 | 22 | 0.420 |
Why?
|
| Sesquiterpenes | 2 | 2013 | 90 | 0.410 |
Why?
|
| Endothelial Cells | 6 | 2016 | 262 | 0.410 |
Why?
|
| Hydrolysis | 5 | 2020 | 69 | 0.400 |
Why?
|
| Mast Cells | 1 | 2013 | 55 | 0.400 |
Why?
|
| COP-Coated Vesicles | 2 | 2025 | 8 | 0.400 |
Why?
|
| Cell Line, Tumor | 15 | 2021 | 1470 | 0.400 |
Why?
|
| Oxidative Stress | 7 | 2019 | 807 | 0.390 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2020 | 339 | 0.390 |
Why?
|
| Metabolomics | 5 | 2021 | 150 | 0.390 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 294 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 145 | 0.380 |
Why?
|
| Sphingomyelin Phosphodiesterase | 3 | 2019 | 11 | 0.380 |
Why?
|
| Drug Delivery Systems | 4 | 2022 | 154 | 0.380 |
Why?
|
| Endoplasmic Reticulum | 2 | 2025 | 111 | 0.370 |
Why?
|
| Solid Phase Extraction | 2 | 2021 | 14 | 0.360 |
Why?
|
| Acetanilides | 2 | 2021 | 3 | 0.350 |
Why?
|
| Nuclear Localization Signals | 1 | 2010 | 6 | 0.350 |
Why?
|
| Neurotensin | 2 | 2024 | 18 | 0.350 |
Why?
|
| Thiazoles | 2 | 2021 | 55 | 0.340 |
Why?
|
| Platelet Activation | 3 | 2020 | 47 | 0.340 |
Why?
|
| Genome-Wide Association Study | 4 | 2014 | 186 | 0.330 |
Why?
|
| Body Weight | 4 | 2021 | 523 | 0.330 |
Why?
|
| Membrane Proteins | 5 | 2015 | 335 | 0.330 |
Why?
|
| Macrophages | 6 | 2021 | 379 | 0.330 |
Why?
|
| Cell Proliferation | 9 | 2020 | 1023 | 0.330 |
Why?
|
| Female | 33 | 2025 | 28171 | 0.330 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 4 | 2018 | 64 | 0.330 |
Why?
|
| Obesity, Morbid | 2 | 2023 | 87 | 0.330 |
Why?
|
| Cell Membrane | 4 | 2025 | 245 | 0.320 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 294 | 0.320 |
Why?
|
| Antifungal Agents | 3 | 2016 | 347 | 0.310 |
Why?
|
| Oxygenases | 3 | 2019 | 16 | 0.310 |
Why?
|
| Cardiovascular System | 1 | 2009 | 53 | 0.310 |
Why?
|
| Nuclear Proteins | 1 | 2010 | 245 | 0.300 |
Why?
|
| Disease Models, Animal | 12 | 2024 | 1478 | 0.300 |
Why?
|
| Receptors, Steroid | 2 | 2021 | 20 | 0.300 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 316 | 0.300 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2008 | 12 | 0.300 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2019 | 44 | 0.290 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 82 | 0.280 |
Why?
|
| HeLa Cells | 7 | 2025 | 265 | 0.280 |
Why?
|
| Cell Line | 8 | 2019 | 1030 | 0.280 |
Why?
|
| Bone Marrow Cells | 3 | 2018 | 190 | 0.280 |
Why?
|
| Coat Protein Complex I | 2 | 2025 | 10 | 0.280 |
Why?
|
| Glutathione | 4 | 2019 | 305 | 0.280 |
Why?
|
| Angiotensin II | 2 | 2022 | 162 | 0.280 |
Why?
|
| Oxazoles | 2 | 2016 | 9 | 0.270 |
Why?
|
| Fatty Acids | 5 | 2024 | 149 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 505 | 0.260 |
Why?
|
| Synapses | 2 | 2018 | 74 | 0.260 |
Why?
|
| Drug Carriers | 4 | 2022 | 73 | 0.260 |
Why?
|
| Lipoproteins, LDL | 3 | 2019 | 169 | 0.260 |
Why?
|
| Biochemistry | 1 | 2006 | 6 | 0.260 |
Why?
|
| Glycosides | 2 | 2016 | 19 | 0.260 |
Why?
|
| Oligopeptides | 2 | 2016 | 92 | 0.250 |
Why?
|
| Phosphatidylinositols | 2 | 2017 | 29 | 0.250 |
Why?
|
| Rhamnose | 2 | 2017 | 6 | 0.250 |
Why?
|
| Neuroprotective Agents | 2 | 2016 | 101 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 2003 | 118 | 0.250 |
Why?
|
| Organophosphorus Compounds | 2 | 2022 | 17 | 0.250 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2015 | 17 | 0.250 |
Why?
|
| Weight Loss | 3 | 2019 | 248 | 0.250 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2025 | 1 | 0.240 |
Why?
|
| Gene Expression Regulation | 7 | 2020 | 990 | 0.240 |
Why?
|
| Triglycerides | 2 | 2024 | 165 | 0.240 |
Why?
|
| S-Adenosylmethionine | 2 | 2016 | 62 | 0.240 |
Why?
|
| Drug Design | 4 | 2015 | 120 | 0.230 |
Why?
|
| Middle Aged | 14 | 2025 | 13028 | 0.230 |
Why?
|
| Aging | 2 | 2024 | 701 | 0.230 |
Why?
|
| Diabetic Angiopathies | 2 | 2018 | 23 | 0.230 |
Why?
|
| Focal Adhesions | 3 | 2017 | 16 | 0.230 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2015 | 80 | 0.230 |
Why?
|
| Community-Acquired Infections | 1 | 2024 | 45 | 0.230 |
Why?
|
| Phenols | 2 | 2016 | 92 | 0.230 |
Why?
|
| Time Factors | 8 | 2024 | 2968 | 0.230 |
Why?
|
| Aminoglycosides | 2 | 2015 | 18 | 0.220 |
Why?
|
| Maternal Exposure | 1 | 2025 | 103 | 0.220 |
Why?
|
| Mammals | 2 | 2019 | 61 | 0.220 |
Why?
|
| Up-Regulation | 5 | 2020 | 454 | 0.220 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 778 | 0.220 |
Why?
|
| Cross Infection | 1 | 2024 | 93 | 0.220 |
Why?
|
| Rhabdomyosarcoma | 2 | 2014 | 13 | 0.220 |
Why?
|
| Adiposity | 3 | 2021 | 143 | 0.220 |
Why?
|
| Blister | 1 | 2023 | 5 | 0.220 |
Why?
|
| Peptides, Cyclic | 2 | 2014 | 42 | 0.220 |
Why?
|
| Doxorubicin | 2 | 2015 | 241 | 0.220 |
Why?
|
| Colorado | 1 | 2023 | 25 | 0.220 |
Why?
|
| Diet, Atherogenic | 3 | 2019 | 10 | 0.210 |
Why?
|
| Bacteremia | 1 | 2024 | 92 | 0.210 |
Why?
|
| Apolipoproteins E | 2 | 2014 | 55 | 0.210 |
Why?
|
| Lipogenesis | 2 | 2021 | 31 | 0.210 |
Why?
|
| Metabolome | 2 | 2021 | 101 | 0.210 |
Why?
|
| Protein Binding | 8 | 2016 | 667 | 0.210 |
Why?
|
| Adult | 10 | 2025 | 14161 | 0.210 |
Why?
|
| Receptors, Purinergic | 2 | 2019 | 12 | 0.210 |
Why?
|
| Inulin | 2 | 2020 | 10 | 0.210 |
Why?
|
| Phosphates | 2 | 2022 | 49 | 0.210 |
Why?
|
| Flame Retardants | 1 | 2022 | 2 | 0.200 |
Why?
|
| Stem Cells | 2 | 2015 | 177 | 0.200 |
Why?
|
| Sarcopenia | 1 | 2024 | 98 | 0.200 |
Why?
|
| Apoptosis | 5 | 2020 | 1119 | 0.200 |
Why?
|
| Blood Glucose | 4 | 2020 | 473 | 0.200 |
Why?
|
| Muscle, Skeletal | 3 | 2024 | 804 | 0.200 |
Why?
|
| Blood Preservation | 2 | 2020 | 27 | 0.200 |
Why?
|
| Homocystinuria | 1 | 2022 | 8 | 0.200 |
Why?
|
| Chitosan | 1 | 2022 | 42 | 0.200 |
Why?
|
| Mutation | 5 | 2017 | 1347 | 0.190 |
Why?
|
| Antioxidants | 3 | 2013 | 256 | 0.190 |
Why?
|
| HEK293 Cells | 7 | 2019 | 229 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2022 | 1542 | 0.190 |
Why?
|
| Nanostructures | 1 | 2022 | 48 | 0.190 |
Why?
|
| Phosphorylation | 7 | 2018 | 528 | 0.190 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 44 | 0.190 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2021 | 17 | 0.190 |
Why?
|
| Cell Polarity | 1 | 2021 | 16 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2024 | 235 | 0.190 |
Why?
|
| Fatty Acids, Volatile | 1 | 2022 | 14 | 0.190 |
Why?
|
| Phenotype | 8 | 2018 | 789 | 0.190 |
Why?
|
| Social Media | 1 | 2024 | 117 | 0.190 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2022 | 51 | 0.180 |
Why?
|
| Adipose Tissue, White | 1 | 2021 | 35 | 0.180 |
Why?
|
| PPAR alpha | 1 | 2021 | 59 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2022 | 79 | 0.180 |
Why?
|
| Aorta | 3 | 2018 | 165 | 0.180 |
Why?
|
| Cell Adhesion | 4 | 2014 | 163 | 0.180 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 117 | 0.180 |
Why?
|
| Diaphragm | 1 | 2021 | 33 | 0.180 |
Why?
|
| Meningitis, Bacterial | 1 | 2021 | 6 | 0.180 |
Why?
|
| Sepsis | 2 | 2021 | 239 | 0.180 |
Why?
|
| Proteome | 2 | 2022 | 171 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 78 | 0.180 |
Why?
|
| Clinical Governance | 1 | 2020 | 1 | 0.180 |
Why?
|
| Egtazic Acid | 1 | 2020 | 11 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 528 | 0.180 |
Why?
|
| Fibrosis | 2 | 2020 | 196 | 0.170 |
Why?
|
| Spermine Synthase | 1 | 2020 | 1 | 0.170 |
Why?
|
| Cold Temperature | 1 | 2020 | 53 | 0.170 |
Why?
|
| Health Surveys | 1 | 2021 | 238 | 0.170 |
Why?
|
| Enzyme Activation | 7 | 2017 | 270 | 0.170 |
Why?
|
| Adrenergic beta-3 Receptor Agonists | 1 | 2020 | 3 | 0.170 |
Why?
|
| Streptococcal Infections | 1 | 2021 | 49 | 0.170 |
Why?
|
| Carbohydrates | 2 | 2017 | 41 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 53 | 0.170 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 483 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2023 | 1046 | 0.170 |
Why?
|
| Nucleotides | 2 | 2014 | 24 | 0.160 |
Why?
|
| Transcription Factor RelB | 1 | 2019 | 3 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 11 | 0.160 |
Why?
|
| Diglycerides | 1 | 2019 | 10 | 0.160 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2019 | 17 | 0.160 |
Why?
|
| I-kappa B Proteins | 1 | 2019 | 16 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 107 | 0.160 |
Why?
|
| Substrate Specificity | 5 | 2014 | 193 | 0.160 |
Why?
|
| 46, XX Disorders of Sex Development | 1 | 2019 | 1 | 0.160 |
Why?
|
| Transcription Factor RelA | 1 | 2019 | 32 | 0.160 |
Why?
|
| X Chromosome | 1 | 2019 | 13 | 0.160 |
Why?
|
| Peroxisomes | 1 | 2019 | 10 | 0.160 |
Why?
|
| Pyocyanine | 1 | 2019 | 1 | 0.160 |
Why?
|
| Hypolipidemic Agents | 1 | 2019 | 29 | 0.160 |
Why?
|
| Cell Survival | 6 | 2020 | 612 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 467 | 0.160 |
Why?
|
| Vesicular Transport Proteins | 2 | 2018 | 38 | 0.160 |
Why?
|
| Dietary Fats | 3 | 2019 | 130 | 0.160 |
Why?
|
| Proteoglycans | 2 | 2018 | 87 | 0.160 |
Why?
|
| Glycerol | 1 | 2019 | 19 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2022 | 330 | 0.160 |
Why?
|
| Receptors, Lysosphingolipid | 4 | 2013 | 7 | 0.160 |
Why?
|
| Streptococcus | 1 | 2019 | 16 | 0.160 |
Why?
|
| Prostaglandin D2 | 1 | 2019 | 22 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 223 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 459 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 211 | 0.150 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2019 | 16 | 0.150 |
Why?
|
| Calcium | 1 | 2020 | 376 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 78 | 0.150 |
Why?
|
| Radiology | 1 | 2020 | 134 | 0.150 |
Why?
|
| Benzoxazoles | 2 | 2020 | 11 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 151 | 0.150 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2018 | 2 | 0.150 |
Why?
|
| Blood-Retinal Barrier | 1 | 2018 | 6 | 0.150 |
Why?
|
| Neural Inhibition | 1 | 2018 | 22 | 0.150 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 14 | 0.150 |
Why?
|
| Central Nervous System Agents | 1 | 2018 | 12 | 0.150 |
Why?
|
| Glucosides | 2 | 2015 | 23 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 37 | 0.150 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 578 | 0.150 |
Why?
|
| Peptides | 2 | 2016 | 223 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2015 | 60 | 0.150 |
Why?
|
| Platelet Transfusion | 2 | 2020 | 33 | 0.150 |
Why?
|
| Mitochondria | 2 | 2019 | 430 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 1 | 2018 | 72 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2019 | 1132 | 0.140 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 378 | 0.140 |
Why?
|
| Acetylglucosamine | 1 | 2017 | 7 | 0.140 |
Why?
|
| Risk | 2 | 2020 | 316 | 0.140 |
Why?
|
| Phthalic Acids | 2 | 2021 | 6 | 0.140 |
Why?
|
| Streptococcus pyogenes | 1 | 2017 | 18 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2017 | 23 | 0.140 |
Why?
|
| Thrombin | 1 | 2017 | 37 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2019 | 216 | 0.140 |
Why?
|
| Rats | 7 | 2022 | 3220 | 0.140 |
Why?
|
| Inflammation Mediators | 3 | 2017 | 115 | 0.140 |
Why?
|
| Mice, Transgenic | 6 | 2018 | 552 | 0.140 |
Why?
|
| Piperazines | 2 | 2020 | 118 | 0.140 |
Why?
|
| Phospholipids | 1 | 2017 | 59 | 0.140 |
Why?
|
| Blood Vessels | 2 | 2015 | 71 | 0.140 |
Why?
|
| Alkaloids | 1 | 2017 | 35 | 0.140 |
Why?
|
| Insulysin | 1 | 2017 | 2 | 0.140 |
Why?
|
| Curcumin | 1 | 2017 | 20 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 1 | 2018 | 75 | 0.140 |
Why?
|
| Inositol Phosphates | 1 | 2017 | 14 | 0.140 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2010 | 7 | 0.140 |
Why?
|
| Sequence Alignment | 2 | 2010 | 125 | 0.140 |
Why?
|
| Deuterium | 2 | 2016 | 46 | 0.140 |
Why?
|
| Myocardial Ischemia | 2 | 2015 | 121 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2013 | 47 | 0.140 |
Why?
|
| Ethers | 1 | 2016 | 8 | 0.140 |
Why?
|
| Retinal Diseases | 1 | 2018 | 56 | 0.140 |
Why?
|
| Endosomes | 1 | 2017 | 36 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 198 | 0.130 |
Why?
|
| Cell Nucleus | 2 | 2015 | 187 | 0.130 |
Why?
|
| Naphthoquinones | 2 | 2013 | 10 | 0.130 |
Why?
|
| Meningitis, Escherichia coli | 1 | 2016 | 1 | 0.130 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2018 | 99 | 0.130 |
Why?
|
| Cholesterol, LDL | 2 | 2023 | 43 | 0.130 |
Why?
|
| Insulin | 3 | 2018 | 479 | 0.130 |
Why?
|
| Isoflavones | 1 | 2017 | 88 | 0.130 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 46 | 0.130 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2016 | 1 | 0.130 |
Why?
|
| Sarcolemma | 1 | 2016 | 3 | 0.130 |
Why?
|
| Transfection | 4 | 2016 | 357 | 0.130 |
Why?
|
| Lipid Peroxides | 1 | 2016 | 10 | 0.130 |
Why?
|
| Lipoproteins | 1 | 2016 | 42 | 0.130 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 48 | 0.130 |
Why?
|
| Catalytic Domain | 4 | 2014 | 60 | 0.130 |
Why?
|
| Kinetics | 4 | 2016 | 626 | 0.130 |
Why?
|
| Docosahexaenoic Acids | 2 | 2019 | 31 | 0.130 |
Why?
|
| Mental Disorders | 2 | 2018 | 428 | 0.130 |
Why?
|
| Steroids | 1 | 2016 | 59 | 0.120 |
Why?
|
| Patient Admission | 1 | 2016 | 78 | 0.120 |
Why?
|
| Durapatite | 1 | 2015 | 23 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2019 | 566 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2017 | 230 | 0.120 |
Why?
|
| Bile Acids and Salts | 1 | 2016 | 80 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2016 | 64 | 0.120 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 4 | 2017 | 33 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 86 | 0.120 |
Why?
|
| Terphenyl Compounds | 1 | 2015 | 1 | 0.120 |
Why?
|
| Hexuronic Acids | 1 | 2015 | 7 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2011 | 312 | 0.120 |
Why?
|
| Down-Regulation | 4 | 2020 | 346 | 0.120 |
Why?
|
| Uridine | 1 | 2015 | 5 | 0.120 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2015 | 5 | 0.120 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 14 | 0.120 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2015 | 6 | 0.120 |
Why?
|
| Multigene Family | 1 | 2015 | 48 | 0.120 |
Why?
|
| Vancomycin | 1 | 2015 | 85 | 0.120 |
Why?
|
| Foam Cells | 1 | 2015 | 17 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2014 | 187 | 0.120 |
Why?
|
| Liposomes | 2 | 2017 | 54 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 240 | 0.120 |
Why?
|
| Glucuronides | 1 | 2015 | 48 | 0.120 |
Why?
|
| Coffea | 1 | 2014 | 1 | 0.120 |
Why?
|
| Chelating Agents | 2 | 2011 | 31 | 0.120 |
Why?
|
| Pregnancy | 2 | 2025 | 2680 | 0.120 |
Why?
|
| Glycosylation | 3 | 2016 | 106 | 0.110 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 1 | 0.110 |
Why?
|
| Lysophosphatidylcholines | 1 | 2014 | 3 | 0.110 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2011 | 33 | 0.110 |
Why?
|
| Thiazolidines | 1 | 2014 | 5 | 0.110 |
Why?
|
| Transcortin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Photoreceptor Cells | 1 | 2014 | 2 | 0.110 |
Why?
|
| Models, Molecular | 4 | 2019 | 348 | 0.110 |
Why?
|
| Genetic Pleiotropy | 1 | 2014 | 3 | 0.110 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2014 | 15 | 0.110 |
Why?
|
| Streptomyces antibioticus | 1 | 2014 | 1 | 0.110 |
Why?
|
| Gene Deletion | 3 | 2020 | 272 | 0.110 |
Why?
|
| Astrocytes | 2 | 2018 | 137 | 0.110 |
Why?
|
| Glycosyltransferases | 1 | 2014 | 10 | 0.110 |
Why?
|
| Carbohydrate Metabolism | 1 | 2014 | 23 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 361 | 0.110 |
Why?
|
| Young Adult | 3 | 2025 | 4329 | 0.110 |
Why?
|
| Methionine Adenosyltransferase | 1 | 2014 | 19 | 0.110 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 243 | 0.110 |
Why?
|
| Capillary Permeability | 1 | 2014 | 27 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 2015 | 125 | 0.110 |
Why?
|
| Archaeal Proteins | 1 | 2014 | 16 | 0.110 |
Why?
|
| Amines | 1 | 2014 | 38 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2014 | 111 | 0.110 |
Why?
|
| Sodium Benzoate | 1 | 2013 | 1 | 0.110 |
Why?
|
| Guanidinoacetate N-Methyltransferase | 1 | 2013 | 1 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2013 | 2 | 0.110 |
Why?
|
| Sulfolobus solfataricus | 1 | 2014 | 22 | 0.110 |
Why?
|
| Amlodipine | 1 | 2013 | 14 | 0.110 |
Why?
|
| Ornithine | 1 | 2013 | 18 | 0.110 |
Why?
|
| Macrolides | 1 | 2013 | 17 | 0.110 |
Why?
|
| Movement Disorders | 1 | 2013 | 16 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2016 | 435 | 0.110 |
Why?
|
| Creatine | 1 | 2013 | 39 | 0.110 |
Why?
|
| Intestinal Mucosa | 3 | 2022 | 224 | 0.110 |
Why?
|
| Language Development Disorders | 1 | 2013 | 18 | 0.110 |
Why?
|
| Mass Spectrometry | 4 | 2017 | 292 | 0.110 |
Why?
|
| Aged | 8 | 2024 | 10121 | 0.110 |
Why?
|
| Rifabutin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Pyrones | 1 | 2013 | 8 | 0.110 |
Why?
|
| Tea | 1 | 2013 | 17 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 20 | 0.110 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2013 | 9 | 0.110 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2013 | 24 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 3392 | 0.110 |
Why?
|
| Chromans | 1 | 2013 | 35 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 68 | 0.110 |
Why?
|
| Actinobacteria | 1 | 2013 | 10 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 505 | 0.110 |
Why?
|
| Aortic Aneurysm | 1 | 2013 | 28 | 0.110 |
Why?
|
| Half-Life | 1 | 2013 | 88 | 0.110 |
Why?
|
| Dyslexia | 1 | 2013 | 41 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2016 | 137 | 0.100 |
Why?
|
| Glycine | 1 | 2013 | 75 | 0.100 |
Why?
|
| Methyltransferases | 1 | 2013 | 29 | 0.100 |
Why?
|
| Stilbenes | 1 | 2013 | 58 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 171 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 179 | 0.100 |
Why?
|
| Disease Progression | 1 | 2016 | 871 | 0.100 |
Why?
|
| Cysteine | 1 | 2013 | 49 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2013 | 29 | 0.100 |
Why?
|
| Thionucleosides | 1 | 2012 | 2 | 0.100 |
Why?
|
| Adenosine Monophosphate | 1 | 2012 | 13 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 160 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2013 | 47 | 0.100 |
Why?
|
| Anion Transport Proteins | 1 | 2012 | 4 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2019 | 665 | 0.100 |
Why?
|
| Structure-Activity Relationship | 4 | 2017 | 404 | 0.100 |
Why?
|
| Risk Factors | 6 | 2024 | 3889 | 0.100 |
Why?
|
| Receptors, Lipoprotein | 1 | 2012 | 7 | 0.100 |
Why?
|
| Carotid Artery Injuries | 1 | 2012 | 13 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 68 | 0.100 |
Why?
|
| Macrophages, Peritoneal | 1 | 2013 | 32 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 122 | 0.100 |
Why?
|
| Base Sequence | 3 | 2015 | 640 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2014 | 192 | 0.100 |
Why?
|
| Glioma | 1 | 2013 | 78 | 0.100 |
Why?
|
| Lymph | 1 | 2012 | 24 | 0.100 |
Why?
|
| Cell Division | 2 | 2003 | 291 | 0.100 |
Why?
|
| Diacylglycerol Kinase | 1 | 2012 | 5 | 0.100 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 29 | 0.100 |
Why?
|
| Erucic Acids | 1 | 2012 | 1 | 0.100 |
Why?
|
| Adenosine | 1 | 2012 | 71 | 0.100 |
Why?
|
| Neurites | 1 | 2012 | 14 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 96 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2013 | 278 | 0.100 |
Why?
|
| Thrombosis | 2 | 2020 | 253 | 0.100 |
Why?
|
| Regeneration | 1 | 2013 | 79 | 0.100 |
Why?
|
| Intellectual Disability | 1 | 2013 | 127 | 0.100 |
Why?
|
| Neurogenesis | 1 | 2012 | 27 | 0.100 |
Why?
|
| Hepatocytes | 1 | 2013 | 190 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 34 | 0.100 |
Why?
|
| Arginine | 1 | 2013 | 182 | 0.100 |
Why?
|
| Axons | 1 | 2012 | 48 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 23 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2012 | 27 | 0.100 |
Why?
|
| Polymers | 2 | 2022 | 49 | 0.100 |
Why?
|
| Protein Phosphatase 1 | 1 | 2011 | 7 | 0.100 |
Why?
|
| Glucose Tolerance Test | 3 | 2021 | 60 | 0.100 |
Why?
|
| RNA Precursors | 1 | 2011 | 9 | 0.100 |
Why?
|
| Pyridinium Compounds | 1 | 2011 | 20 | 0.100 |
Why?
|
| Glycoproteins | 3 | 2013 | 122 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 89 | 0.090 |
Why?
|
| Hematocrit | 1 | 2011 | 44 | 0.090 |
Why?
|
| Autophagy | 1 | 2013 | 193 | 0.090 |
Why?
|
| Clot Retraction | 1 | 2011 | 1 | 0.090 |
Why?
|
| rap GTP-Binding Proteins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mercury | 1 | 2011 | 8 | 0.090 |
Why?
|
| Platelet Adhesiveness | 1 | 2011 | 13 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 399 | 0.090 |
Why?
|
| Methionine | 3 | 2018 | 136 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 4 | 2016 | 242 | 0.090 |
Why?
|
| Shock, Septic | 1 | 2013 | 82 | 0.090 |
Why?
|
| Fibroblasts | 2 | 2012 | 355 | 0.090 |
Why?
|
| Adipose Tissue, Brown | 1 | 2012 | 44 | 0.090 |
Why?
|
| Cholesterol | 2 | 2023 | 153 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 52 | 0.090 |
Why?
|
| Phosphatidylcholines | 2 | 2025 | 27 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 221 | 0.090 |
Why?
|
| Heart Failure | 1 | 2017 | 565 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2011 | 62 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 406 | 0.090 |
Why?
|
| Isotope Labeling | 2 | 2013 | 57 | 0.090 |
Why?
|
| Anemia | 1 | 2011 | 74 | 0.090 |
Why?
|
| Catechin | 1 | 2011 | 16 | 0.090 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 18 | 0.090 |
Why?
|
| Golgi Apparatus | 2 | 2025 | 101 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2011 | 22 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 181 | 0.090 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 24 | 0.090 |
Why?
|
| Protein Interaction Maps | 2 | 2022 | 27 | 0.090 |
Why?
|
| Protein Precursors | 2 | 2024 | 42 | 0.090 |
Why?
|
| alpha Karyopherins | 1 | 2010 | 1 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 34 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2013 | 177 | 0.090 |
Why?
|
| Amidines | 1 | 2010 | 6 | 0.090 |
Why?
|
| Exercise | 1 | 2015 | 547 | 0.080 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Group V Phospholipases A2 | 1 | 2010 | 1 | 0.080 |
Why?
|
| Platelet Aggregation | 4 | 2012 | 72 | 0.080 |
Why?
|
| Membrane Lipids | 1 | 2010 | 13 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 169 | 0.080 |
Why?
|
| Macrophage Activation | 1 | 2010 | 24 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 150 | 0.080 |
Why?
|
| Organ Specificity | 2 | 2021 | 115 | 0.080 |
Why?
|
| Cerebellum | 1 | 2011 | 125 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 163 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 177 | 0.080 |
Why?
|
| Crystallography, X-Ray | 3 | 2016 | 156 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2010 | 183 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 155 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2015 | 253 | 0.080 |
Why?
|
| Neurons | 1 | 2012 | 418 | 0.080 |
Why?
|
| Scotland | 2 | 2020 | 9 | 0.080 |
Why?
|
| Catalysis | 3 | 2014 | 88 | 0.080 |
Why?
|
| Fibrinogen | 2 | 2011 | 34 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 118 | 0.080 |
Why?
|
| Hemostasis | 1 | 2009 | 60 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 234 | 0.070 |
Why?
|
| Binding Sites | 3 | 2017 | 377 | 0.070 |
Why?
|
| Bilirubin | 2 | 2023 | 43 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 560 | 0.070 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 213 | 0.070 |
Why?
|
| Leukocytes | 1 | 2008 | 66 | 0.070 |
Why?
|
| Indoles | 3 | 2019 | 278 | 0.070 |
Why?
|
| Models, Biological | 2 | 2021 | 735 | 0.070 |
Why?
|
| CHO Cells | 3 | 2013 | 125 | 0.070 |
Why?
|
| Cricetinae | 3 | 2013 | 194 | 0.070 |
Why?
|
| Genotype | 3 | 2014 | 566 | 0.070 |
Why?
|
| Adenosine Triphosphate | 2 | 2011 | 205 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2008 | 76 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 603 | 0.070 |
Why?
|
| Hep G2 Cells | 2 | 2019 | 39 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 461 | 0.070 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 36 | 0.070 |
Why?
|
| 3T3-L1 Cells | 2 | 2019 | 13 | 0.070 |
Why?
|
| Carbon Radioisotopes | 1 | 2007 | 54 | 0.070 |
Why?
|
| Coronary Disease | 1 | 2008 | 152 | 0.070 |
Why?
|
| Mice, Obese | 2 | 2019 | 22 | 0.070 |
Why?
|
| Octoxynol | 1 | 2006 | 7 | 0.070 |
Why?
|
| Chromatography, Thin Layer | 1 | 2006 | 25 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5422 | 0.060 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 256 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2007 | 128 | 0.060 |
Why?
|
| Cell Count | 2 | 2020 | 149 | 0.060 |
Why?
|
| Intestines | 2 | 2018 | 154 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2020 | 265 | 0.060 |
Why?
|
| Cytoskeleton | 2 | 2018 | 39 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 105 | 0.060 |
Why?
|
| Glutathione Disulfide | 2 | 2015 | 38 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2017 | 121 | 0.060 |
Why?
|
| Appalachian Region | 2 | 2016 | 12 | 0.060 |
Why?
|
| Pregnancy Trimesters | 1 | 2025 | 13 | 0.060 |
Why?
|
| Computational Biology | 2 | 2019 | 212 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2017 | 136 | 0.060 |
Why?
|
| Energy Metabolism | 2 | 2017 | 302 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 30 | 0.060 |
Why?
|
| Biological Transport | 1 | 2025 | 160 | 0.060 |
Why?
|
| Protein Transport | 2 | 2019 | 180 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2016 | 192 | 0.060 |
Why?
|
| Wound Healing | 2 | 2020 | 219 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2015 | 49 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 278 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 25 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2014 | 16 | 0.050 |
Why?
|
| COS Cells | 2 | 2017 | 73 | 0.050 |
Why?
|
| Chemotactic Factors | 2 | 2014 | 3 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2024 | 374 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2004 | 86 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 31 | 0.050 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2003 | 1 | 0.050 |
Why?
|
| Biotinylation | 1 | 2003 | 27 | 0.050 |
Why?
|
| Reverse Transcription | 1 | 2003 | 4 | 0.050 |
Why?
|
| Suramin | 1 | 2003 | 10 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2003 | 14 | 0.050 |
Why?
|
| Phospholipases A2 | 1 | 2003 | 15 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 166 | 0.050 |
Why?
|
| Random Allocation | 2 | 2016 | 285 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2003 | 66 | 0.050 |
Why?
|
| Biotin | 1 | 2003 | 46 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 140 | 0.050 |
Why?
|
| Urobilin | 1 | 2023 | 1 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 202 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 243 | 0.050 |
Why?
|
| Language | 1 | 2024 | 138 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2023 | 70 | 0.050 |
Why?
|
| Fatty Liver | 2 | 2016 | 142 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 59 | 0.050 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2013 | 13 | 0.050 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 2 | 2013 | 11 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 747 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 67 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1378 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 460 | 0.050 |
Why?
|
| Particle Size | 1 | 2022 | 82 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2022 | 13 | 0.050 |
Why?
|
| Thiazolidinediones | 2 | 2015 | 83 | 0.050 |
Why?
|
| Cricetulus | 2 | 2013 | 104 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2012 | 70 | 0.050 |
Why?
|
| Sex Factors | 2 | 2019 | 727 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2022 | 58 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 925 | 0.050 |
Why?
|
| Kidney | 1 | 2007 | 707 | 0.050 |
Why?
|
| Adolescent | 3 | 2023 | 6739 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 145 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2021 | 21 | 0.050 |
Why?
|
| Bone Marrow | 2 | 2014 | 364 | 0.050 |
Why?
|
| Mesylates | 1 | 2021 | 3 | 0.050 |
Why?
|
| Homocysteine | 1 | 2022 | 126 | 0.050 |
Why?
|
| Ubiquinone | 1 | 2021 | 14 | 0.050 |
Why?
|
| Organ Size | 1 | 2021 | 228 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2021 | 24 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2022 | 72 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 6607 | 0.040 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 338 | 0.040 |
Why?
|
| Mental Health | 1 | 2024 | 240 | 0.040 |
Why?
|
| Isotopes | 1 | 2021 | 25 | 0.040 |
Why?
|
| Streptococcus agalactiae | 1 | 2021 | 15 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2022 | 2867 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2022 | 139 | 0.040 |
Why?
|
| Myelopoiesis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 150 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 132 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 2011 | 68 | 0.040 |
Why?
|
| Interferon-beta | 1 | 2020 | 33 | 0.040 |
Why?
|
| Polyamines | 1 | 2020 | 8 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 21 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2020 | 53 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2016 | 1327 | 0.040 |
Why?
|
| Prebiotics | 1 | 2020 | 2 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 95 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1678 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 153 | 0.040 |
Why?
|
| Brain | 2 | 2022 | 1323 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2011 | 326 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 259 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 115 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 199 | 0.040 |
Why?
|
| Sex-Determining Region Y Protein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Swine | 2 | 2011 | 428 | 0.040 |
Why?
|
| Amino Acids | 1 | 2021 | 377 | 0.040 |
Why?
|
| Caspase 7 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 39 | 0.040 |
Why?
|
| Cachexia | 1 | 2019 | 27 | 0.040 |
Why?
|
| Arkansas | 1 | 2025 | 2028 | 0.040 |
Why?
|
| Testis | 1 | 2019 | 72 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2019 | 95 | 0.040 |
Why?
|
| Ovary | 1 | 2019 | 107 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 2011 | 246 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cell Extracts | 1 | 2018 | 6 | 0.040 |
Why?
|
| Thioredoxins | 1 | 2019 | 26 | 0.040 |
Why?
|
| Secretory Pathway | 1 | 2018 | 4 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 50 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2018 | 34 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2019 | 115 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2018 | 36 | 0.040 |
Why?
|
| Pluripotent Stem Cells | 1 | 2018 | 7 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 1026 | 0.040 |
Why?
|
| Software | 1 | 2020 | 280 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2018 | 26 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2018 | 42 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2018 | 57 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2018 | 53 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 605 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 585 | 0.040 |
Why?
|
| Amidohydrolases | 1 | 2017 | 6 | 0.040 |
Why?
|
| Azocines | 1 | 2017 | 2 | 0.040 |
Why?
|
| Quinolizines | 1 | 2017 | 2 | 0.040 |
Why?
|
| Choline Deficiency | 1 | 2017 | 23 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2018 | 77 | 0.040 |
Why?
|
| Peptidoglycan | 1 | 2017 | 16 | 0.040 |
Why?
|
| Ketamine | 1 | 2018 | 59 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2018 | 63 | 0.040 |
Why?
|
| Acrylates | 1 | 2017 | 3 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2011 | 537 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2018 | 104 | 0.030 |
Why?
|
| Mitochondria, Heart | 1 | 2017 | 37 | 0.030 |
Why?
|
| Vitrectomy | 1 | 2018 | 61 | 0.030 |
Why?
|
| Enzymes, Immobilized | 1 | 2017 | 5 | 0.030 |
Why?
|
| Androstadienes | 1 | 2017 | 12 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2017 | 16 | 0.030 |
Why?
|
| Coal | 1 | 2016 | 2 | 0.030 |
Why?
|
| Crystallization | 1 | 2017 | 33 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 46 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 178 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 57 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 721 | 0.030 |
Why?
|
| Immunochemistry | 1 | 2016 | 5 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 198 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 111 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 206 | 0.030 |
Why?
|
| Enteroendocrine Cells | 1 | 2016 | 1 | 0.030 |
Why?
|
| Fat Body | 1 | 2016 | 8 | 0.030 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2016 | 1 | 0.030 |
Why?
|
| Hydroxycholesterols | 1 | 2016 | 9 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2017 | 120 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 31 | 0.030 |
Why?
|
| Food-Drug Interactions | 1 | 2016 | 14 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 329 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 70 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2016 | 77 | 0.030 |
Why?
|
| Phosphopeptides | 1 | 2016 | 7 | 0.030 |
Why?
|
| Medical Records | 1 | 2016 | 87 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 387 | 0.030 |
Why?
|
| Somatosensory Cortex | 1 | 2016 | 5 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 857 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 185 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 43 | 0.030 |
Why?
|
| Debridement | 1 | 2015 | 48 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2016 | 111 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 465 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 2016 | 67 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 73 | 0.030 |
Why?
|
| Melanoma | 1 | 2019 | 288 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 72 | 0.030 |
Why?
|
| Transaldolase | 1 | 2015 | 1 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 3 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2015 | 97 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 90 | 0.030 |
Why?
|
| Heme | 1 | 2015 | 21 | 0.030 |
Why?
|
| Threonine | 1 | 2015 | 15 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2015 | 13 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 590 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 373 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2015 | 55 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 112 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 129 | 0.030 |
Why?
|
| Bronchi | 1 | 2015 | 43 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 451 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 20 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2015 | 118 | 0.030 |
Why?
|
| Cell Communication | 1 | 2015 | 71 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 124 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2014 | 39 | 0.030 |
Why?
|
| Isoxazoles | 1 | 2014 | 15 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 28 | 0.030 |
Why?
|
| Propionates | 1 | 2014 | 24 | 0.030 |
Why?
|
| Exome | 1 | 2014 | 55 | 0.030 |
Why?
|
| Brachiocephalic Trunk | 1 | 2014 | 6 | 0.030 |
Why?
|
| Coal Mining | 1 | 2014 | 4 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2014 | 56 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 108 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 88 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2014 | 26 | 0.030 |
Why?
|
| Critical Care | 1 | 2016 | 222 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 57 | 0.030 |
Why?
|
| Nitrophenols | 1 | 2014 | 17 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2014 | 20 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2014 | 15 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2014 | 49 | 0.030 |
Why?
|
| Receptor, TIE-2 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Light | 1 | 2014 | 73 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 56 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 182 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 51 | 0.030 |
Why?
|
| Integrases | 1 | 2014 | 44 | 0.030 |
Why?
|
| Naphthols | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cyclization | 1 | 2013 | 5 | 0.030 |
Why?
|
| Glutarates | 1 | 2013 | 8 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2016 | 312 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2013 | 101 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 40 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 92 | 0.030 |
Why?
|
| Micromonospora | 1 | 2013 | 1 | 0.030 |
Why?
|
| Enediynes | 1 | 2013 | 1 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 223 | 0.030 |
Why?
|
| Salmonella enterica | 1 | 2013 | 17 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 208 | 0.030 |
Why?
|
| Talin | 1 | 2013 | 3 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 8 | 0.030 |
Why?
|
| Integrin beta Chains | 1 | 2013 | 14 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2014 | 183 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2015 | 215 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 119 | 0.030 |
Why?
|
| Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 111 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 92 | 0.030 |
Why?
|
| Caspases | 1 | 2013 | 104 | 0.030 |
Why?
|
| beta-Defensins | 1 | 2013 | 4 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 22 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2013 | 28 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2013 | 12 | 0.030 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 2013 | 7 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 54 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2012 | 3 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2013 | 30 | 0.030 |
Why?
|
| Epoprostenol | 1 | 2012 | 16 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2012 | 19 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2013 | 49 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2013 | 25 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 706 | 0.030 |
Why?
|
| Neointima | 1 | 2012 | 5 | 0.030 |
Why?
|
| rho-Associated Kinases | 1 | 2012 | 18 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 32 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 72 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 43 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 83 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2013 | 51 | 0.020 |
Why?
|
| Actins | 1 | 2013 | 115 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 285 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2012 | 44 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2012 | 91 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 187 | 0.020 |
Why?
|
| Lysine | 1 | 2013 | 89 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 86 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1563 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 618 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2012 | 98 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 82 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2013 | 176 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2012 | 16 | 0.020 |
Why?
|
| Adipokines | 1 | 2012 | 10 | 0.020 |
Why?
|
| Insulinoma | 1 | 2012 | 7 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 284 | 0.020 |
Why?
|
| Paxillin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2012 | 67 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 11 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2013 | 256 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2012 | 19 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 57 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2012 | 14 | 0.020 |
Why?
|
| Lyases | 1 | 2011 | 2 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 326 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 119 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 19 | 0.020 |
Why?
|
| Domperidone | 1 | 2011 | 2 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 18 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2012 | 41 | 0.020 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Vinculin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2011 | 13 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 17 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 95 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2015 | 494 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2012 | 153 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 108 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 218 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 30 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2011 | 33 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 71 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 2481 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 89 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 639 | 0.020 |
Why?
|
| P-Selectin | 1 | 2011 | 30 | 0.020 |
Why?
|
| Ion Channels | 1 | 2012 | 70 | 0.020 |
Why?
|
| Fibronectins | 1 | 2011 | 37 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 102 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2011 | 84 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 558 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 206 | 0.020 |
Why?
|
| Caveolae | 1 | 2011 | 6 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 220 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2011 | 5 | 0.020 |
Why?
|
| Borohydrides | 1 | 2010 | 1 | 0.020 |
Why?
|
| Neuroprostanes | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cyclopentanes | 1 | 2010 | 12 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 45 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 53 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2010 | 33 | 0.020 |
Why?
|
| Motor Skills | 1 | 2011 | 26 | 0.020 |
Why?
|
| Superoxides | 1 | 2010 | 46 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 128 | 0.020 |
Why?
|
| Asthma | 1 | 2015 | 316 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2012 | 258 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 488 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 2010 | 9 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 199 | 0.020 |
Why?
|
| Lipolysis | 1 | 2010 | 11 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 74 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1201 | 0.020 |
Why?
|
| Albumins | 1 | 2010 | 32 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 130 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1006 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 146 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2010 | 88 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 216 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 123 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 333 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 979 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2008 | 97 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 313 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 636 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2009 | 209 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 891 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 3733 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 4076 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1132 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2004 | 46 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 48 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 94 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 405 | 0.010 |
Why?
|
| Child | 1 | 2013 | 7248 | 0.010 |
Why?
|